These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 33488111)

  • 1. Challenges of Genomic Testing for Hereditary Breast and Ovarian Cancers.
    McAlarnen L; Stearns K; Uyar D
    Appl Clin Genet; 2021; 14():1-9. PubMed ID: 33488111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Validity of Next-Generation Sequencing Multi-Gene Panel Testing for Detecting Pathogenic Variants in Patients With Hereditary Breast-Ovarian Cancer Syndrome.
    Yoo J; Lee GD; Kim JH; Lee SN; Chae H; Han E; Kim Y; Kim M
    Ann Lab Med; 2020 Mar; 40(2):148-154. PubMed ID: 31650731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germline mutational variants of Turkish ovarian cancer patients suspected of Hereditary Breast and Ovarian Cancer (HBOC) by next-generation sequencing.
    Tuncer SB; Celik B; Erciyas SK; Erdogan OS; Gültaslar BK; Odemis DA; Avsar M; Sen F; Saip PM; Yazici H
    Pathol Res Pract; 2024 Feb; 254():155075. PubMed ID: 38219492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of the cost-effectiveness of genetic testing for germline variants in familial cancer.
    Teppala S; Hodgkinson B; Hayes S; Scuffham P; Tuffaha H
    J Med Econ; 2023; 26(1):19-33. PubMed ID: 36426964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients.
    Rodríguez-Balada M; Roig B; Melé M; Albacar C; Serrano S; Salvat M; Querol M; Borràs J; Martorell L; Gumà J
    Clin Biochem; 2020 Feb; 76():17-23. PubMed ID: 31786208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Next Generation Sequencing-Based Germline Panel Testing for Breast and Ovarian Cancers in Pakistan.
    Tariq H; Gul A; Khadim T; Ud-Din H; Tipu HN; Asif M; Ahmed R
    Asian Pac J Cancer Prev; 2021 Mar; 22(3):719-724. PubMed ID: 33773534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer Predisposition Cascade Screening for Hereditary Breast/Ovarian Cancer and Lynch Syndromes in Switzerland: Study Protocol.
    Katapodi MC; Viassolo V; Caiata-Zufferey M; Nikolaidis C; Bührer-Landolt R; Buerki N; Graffeo R; Horváth HC; Kurzeder C; Rabaglio M; Scharfe M; Urech C; Erlanger TE; Probst-Hensch N; Heinimann K; Heinzelmann-Schwarz V; Pagani O; Chappuis PO
    JMIR Res Protoc; 2017 Sep; 6(9):e184. PubMed ID: 28931501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Current clinical issues and recent trends in hereditary breast and ovarian cancer in Japan-genetic testing for HBOC and risk-reducing surgery].
    Arai M; Iwase T; Takazawa Y; Takeshima N
    Gan To Kagaku Ryoho; 2014 Nov; 41(11):1333-9. PubMed ID: 25434434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germline mutations of 4567 patients with hereditary breast-ovarian cancer spectrum in Thailand.
    Kansuttiviwat C; Lertwilaiwittaya P; Roothumnong E; Nakthong P; Dungort P; Meesamarnpong C; Tansa-Nga W; Pongsuktavorn K; Wiboonthanasarn S; Tititumjariya W; Phuphuripan N; Lertbussarakam C; Wattanarangsan J; Sritun J; Punuch K; Kammarabutr J; Mutirangura P; Thongnoppakhun W; Limwongse C; Pithukpakorn M
    NPJ Genom Med; 2024 Feb; 9(1):9. PubMed ID: 38355628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of ovarian and breast cancer risk in non-BRCA HBOC pathogenic variant carriers in a large California health care system.
    Powell CB; Laurent C; Garcia C; Hoodfar E; Karlea A; Kobelka C; Lee J; Roh J; Kushi LH
    Gynecol Oncol; 2022 Dec; 167(3):467-475. PubMed ID: 36220669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center.
    Arun BK; Peterson SK; Sweeney LE; Bluebond RD; Tidwell RSS; Makhnoon S; Kushwaha AC
    Cancer; 2022 Jan; 128(1):94-102. PubMed ID: 34424535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using a Tailored Digital Health Intervention for Family Communication and Cascade Genetic Testing in Swiss and Korean Families With Hereditary Breast and Ovarian Cancer: Protocol for the DIALOGUE Study.
    Kim S; Aceti M; Baroutsou V; Bürki N; Caiata-Zufferey M; Cattaneo M; Chappuis PO; Ciorba FM; Graffeo-Galbiati R; Heinzelmann-Schwarz V; Jeong J; Jung MM; Kim SW; Kim J; Lim MC; Ming C; Monnerat C; Park HS; Park SH; Pedrazzani CA; Rabaglio M; Ryu JM; Saccilotto R; Wieser S; Zürrer-Härdi U; Katapodi MC
    JMIR Res Protoc; 2021 Jun; 10(6):e26264. PubMed ID: 34114954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?
    Eliade M; Skrzypski J; Baurand A; Jacquot C; Bertolone G; Loustalot C; Coutant C; Guy F; Fumoleau P; Duffourd Y; Arnould L; Delignette A; Padéano MM; Lepage C; Raichon-Patru G; Boudrant A; Bône-Lépinoy MC; Villing AL; Charpin A; Peignaux K; Chevrier S; Vegran F; Ghiringhelli F; Boidot R; Sevenet N; Lizard S; Faivre L
    Oncotarget; 2017 Jan; 8(2):1957-1971. PubMed ID: 27779110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening of BRCA1/2 genes mutations and copy number variations in patients with high risk for hereditary breast and ovarian cancer syndrome (HBOC).
    El Ansari FZ; Jouali F; Marchoudi N; Bennani MM; Ghailani NN; Barakat A; Fekkak J
    BMC Cancer; 2020 Aug; 20(1):747. PubMed ID: 32778078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hereditary Breast and Ovarian Cancer: An Updated Primer for OB/GYNs.
    Bellcross CA
    Obstet Gynecol Clin North Am; 2022 Mar; 49(1):117-147. PubMed ID: 35168766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The uptake of presymptomatic genetic testing in hereditary breast-ovarian cancer and Lynch syndrome: a systematic review of the literature and implications for clinical practice.
    Menko FH; Ter Stege JA; van der Kolk LE; Jeanson KN; Schats W; Moha DA; Bleiker EMA
    Fam Cancer; 2019 Jan; 18(1):127-135. PubMed ID: 29846880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementation of multigene panel testing for breast and ovarian cancer in South Africa: A step towards excellence in oncology for the public sector.
    van der Merwe NC; Ntaita KS; Stofberg H; Combrink HM; Oosthuizen J; Kotze MJ
    Front Oncol; 2022; 12():938561. PubMed ID: 36568162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of medical knowledge toward genetic testing for individuals with hereditary breast and ovarian cancer syndrome in Brazil.
    Lasta JL; Groto AD; Brandalize APC
    Prev Med Rep; 2023 Oct; 35():102356. PubMed ID: 37649554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of twenty-nine novel germline unclassified variants of BRCA1 and BRCA2 genes in 1400 Italian individuals.
    Santonocito C; Scapaticci M; Guarino D; Bartolini A; Minucci A; Concolino P; Scambia G; Paris I; Capoluongo E
    Breast; 2017 Dec; 36():74-78. PubMed ID: 29020660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic yield and clinical relevance of expanded germline genetic testing for nearly 7000 suspected HBOC patients.
    Henkel J; Laner A; Locher M; Wohlfrom T; Neitzel B; Becker K; Neuhann T; Abicht A; Steinke-Lange V; Holinski-Feder E
    Eur J Hum Genet; 2023 Aug; 31(8):925-930. PubMed ID: 37188824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.